Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Journal of Personalized Medicine|December 23, 2023
Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily PracticeFernando Ramos, María Lourdes Hermosín, Marta Fuertes-Núñez, et al.
Frontiers in Oncology|December 12, 2022
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patientsSara Villar, Beñat Ariceta, Xabier Agirre, et al.
Annals of Hematology|February 3, 2018
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemiaDavid Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, et al.
Annals of Hematology|February 24, 2018
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemiaDavid Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, et al.
European Journal of Haematology|April 4, 2020
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocolsMarta Sitges, Blanca Boluda, Ana Garrido, et al.
Leukemia & Lymphoma|May 10, 2019
Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registryOlga Salamero, David Martínez-Cuadrón, Marta Sobas, et al.
Leukemia|November 14, 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registriesChristian Récher, Christoph Röllig, Emilie Bérard, et al.
British Journal of Haematology|April 11, 2014
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletionJoaquín Sánchez-García, Consuelo Del Cañizo, Ignacio Lorenzo, et al.
Blood Cancer Journal|July 12, 2022
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registriesEmilie Bérard, Christoph Röllig, Sarah Bertoli, et al.
British Journal of Haematology|April 28, 2016
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemiaJuan M Bergua, Pau Montesinos, David Martinez-Cuadrón, et al.
Pageof 9